Helixmith’s Plasmid DNA Therapeutic Moves Forward With New Formulation
Non-Viral Gene Therapy Set For Mass Production
South Korea's Helixmith reaches a milestone with a US FDA nod to use a new in-house developed formulation for its plasmid DNA therapeutic Engensis, said to be more suited to mass production, in its upcoming Phase III trials for diabetic peripheral neuropathy.
